No Data
No Data
Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Shift From Loss To Profit
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Tarsus Pharmaceuticals, Inc., a
When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?
BofA Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
BofA Securities analyst Jason Gerberry maintains $Tarsus Pharmaceuticals(TARS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average return of -
Express News | Tarsus Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $61 From $63
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Most Shareholders Will Probably Agree With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) CEO Compensation
Key Insights Tarsus Pharmaceuticals' Annual General Meeting to take place on 13th of June Salary of US$619.5k is part of CEO Bobby Azamian's total remuneration The overall pay is 49% below the ind